Get all your news in one place.
100's of premium titles.
One app.
Start reading
Barchart
Barchart
Jim Van Meerten

This Stock Is Up 704% in 2025 But Has No Products to Its Name

  • Relmada Therapeutics (RLMD) is a clinical-stage pharma company with no commercialized products and a $141 million market cap.
  • RLMD has shown strong technical momentum, gaining 440% since August.
  • Shares have a 100% “Buy” technical opinion from Barchart.
  • Despite technical strength, RLMD lacks revenue, faces pipeline setbacks, and is rated “Hold” on Wall Street. 

Author’s Note: Investments are judged by revenue, earnings, cash flow, and dividends – that’s Investing 101. This company was founded in 2004 and, 21 years later, has never sold a dime of product. This is not investing. This is speculation. Two words: Due Diligence

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.